Abiraterone is an anticancer chemotherapeutic compound that is used to treat castration-resistant prostate cancer. Abiratone inhibits the enzyme Cytochrome p450 17α-hydroxylase (Cyp17), reducing androgen production. This compound may also directly decrease levels of androgen receptor protein expression and inhibit eIF4F signaling.
| Cas No. | 154229-19-3 |
|---|---|
| Purity | ≥99% |
| Formula | C24H31NO |
| Formula Wt. | 349.51 |
| IUPAC Name | (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol |
| Solubility | MeOH |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | A0534 Info Sheet PDF |
|---|
Ryan CJ, Cheng ML. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother. 2013 Jan;14(1):91-6. PMID: 23199349.
Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther. 2012;6:13-8. PMID: 22291466.
Soifer HS, Souleimanian N, Wu S, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem. 2012 Feb 3;287(6):3777-87. PMID: 22174412.
